Parataxis Korea, Inc. (KOSDAQ:288330)

South Korea · Delayed Price · Currency is KRW

416.00

-13.00 (-3.03%)

At close: Apr 7, 2026

-94.46% (1Y)

Market Cap	44.13B -88.7%
Revenue (ttm)	319.22M +2,755.8%
Net Income	-28.66B
EPS	-343.73
Shares Out	106.08M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	7,270,537
Open	432.00
Previous Close	429.00
Day's Range	392.00 - 557.00
52-Week Range	392.00 - 9,280.00
Beta	1.68
Analysts	n/a
Price Target	n/a
Earnings Date	Aug 18, 2026

About Parataxis Korea

Parataxis Korea, Inc., a clinical stage biotech company, engages in the development of therapeutics for the treatment of ulcerative colitis, fibrotic diseases, and cancers worldwide. Its products in pipeline includes BBT-401, a Pellino-1 inhibitor, which is in Phase I clinical trial for the treatment of ulcerative colitis; and BBT-877, an autotaxin inhibitor that is in Phase I clinical trial for the treatment of various fibrotic diseases, such as idiopathic pulmonary fibrosis. Bridge Biotherapeutics, Inc. has a research collaboration with Atomw... [Read more]

Industry Biological Products, Except Diagnostic Substances

Founded 2015

Employees 21

Stock Exchange KOSDAQ

Ticker Symbol 288330

Full Company Profile

Financial Performance

In 2025, Parataxis Korea's revenue was 9.00 million, an increase of 313.21% compared to the previous year's 2.18 million. Losses were -31.00 billion, 56.9% more than in 2024.

Financial Statements